258 related articles for article (PubMed ID: 17374831)
1. FDA starts moving on critical path, but initiative running out of steam.
Finkelstein JB
J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
[No Abstract] [Full Text] [Related]
2. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
3. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
4. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
[TBL] [Abstract][Full Text] [Related]
5. Business barriers slowing the pace of cancer immunotherapy research and development.
Tuma RS
J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
[No Abstract] [Full Text] [Related]
6. Should the FDA be the doctor of last resort?
DeVita VT
Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
[No Abstract] [Full Text] [Related]
7. Advancing Alzheimer's disease drug review as a national priority.
Perry DP
Alzheimers Dement; 2009 Mar; 5(2):180-1. PubMed ID: 19328455
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy as drug development.
Carter BJ
Mol Ther; 2000 Mar; 1(3):211-2. PubMed ID: 10933936
[No Abstract] [Full Text] [Related]
9. Translation of cancer immunotherapies.
Skipper J; Hoffman EW; O'Donnell-Tormey J; Old LJ
Nat Med; 2004 Nov; 10(11):1154-5; author reply 1155. PubMed ID: 15516901
[No Abstract] [Full Text] [Related]
10. Market watch: Upcoming catalysts in Q1 2015.
Uribe A
Nat Rev Drug Discov; 2015 Jan; 14(1):9. PubMed ID: 25503330
[No Abstract] [Full Text] [Related]
11. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
[No Abstract] [Full Text] [Related]
12. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
13. Accelerated approval dust begins to settle.
Mullard A
Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
[No Abstract] [Full Text] [Related]
14. Patient group seeks overhaul of FDA clinical trial system in court.
Hede K
J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
[No Abstract] [Full Text] [Related]
15. Slow start to phase 0 as researchers debate value.
Twombly R
J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
[No Abstract] [Full Text] [Related]
16. The critical path to medical innovation.
Williams D
Med Device Technol; 2004 Jun; 15(5):8-10. PubMed ID: 15285478
[TBL] [Abstract][Full Text] [Related]
17. Development of the pill.
García CR
Ann N Y Acad Sci; 2004 Dec; 1038():223-6. PubMed ID: 15838117
[TBL] [Abstract][Full Text] [Related]
18. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.
Rock EP; Scott JA; Kennedy DL; Sridhara R; Pazdur R; Burke LB
J Natl Cancer Inst Monogr; 2007; (37):27-30. PubMed ID: 17951228
[TBL] [Abstract][Full Text] [Related]
19. Vision and will: the future of the FDA.
Epstein D
Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098
[No Abstract] [Full Text] [Related]
20. Laetrilomania--again.
Relman AS
N Engl J Med; 1978 Jan; 298(4):215-6. PubMed ID: 339088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
